Dynasty Wealth Management LLC Acquires New Stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Dynasty Wealth Management LLC acquired a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 558 shares of the company's stock, valued at approximately $234,000.

Several other hedge funds also recently bought and sold shares of IDXX. United Capital Financial Advisors LLC increased its stake in shares of IDEXX Laboratories by 0.9% during the 4th quarter. United Capital Financial Advisors LLC now owns 2,446 shares of the company's stock valued at $1,011,000 after acquiring an additional 22 shares during the last quarter. Sage Mountain Advisors LLC increased its holdings in IDEXX Laboratories by 3.8% during the 1st quarter. Sage Mountain Advisors LLC now owns 635 shares of the company's stock worth $267,000 after purchasing an additional 23 shares during the last quarter. PDS Planning Inc increased its holdings in IDEXX Laboratories by 3.9% in the first quarter. PDS Planning Inc now owns 641 shares of the company's stock valued at $269,000 after buying an additional 24 shares during the last quarter. Gabelli Funds LLC raised its position in shares of IDEXX Laboratories by 5.3% during the 4th quarter. Gabelli Funds LLC now owns 500 shares of the company's stock valued at $207,000 after acquiring an additional 25 shares in the last quarter. Finally, Bigelow Investment Advisors LLC lifted its position in shares of IDEXX Laboratories by 1.9% in the 1st quarter. Bigelow Investment Advisors LLC now owns 1,420 shares of the company's stock worth $596,000 after buying an additional 27 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,260 shares of the stock in a transaction dated Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total value of $645,548.40. Following the completion of the sale, the director directly owned 1,801 shares in the company, valued at $922,724.34. This represents a 41.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 0.98% of the company's stock.

IDEXX Laboratories Trading Down 0.8%

IDXX traded down $4.10 during mid-day trading on Friday, reaching $514.61. The stock had a trading volume of 329,531 shares, compared to its average volume of 643,129. The firm's fifty day simple moving average is $523.12 and its two-hundred day simple moving average is $462.00. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.81 and a current ratio of 1.16. The stock has a market capitalization of $41.38 billion, a P/E ratio of 47.56, a P/E/G ratio of 3.77 and a beta of 1.54. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $549.52.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, beating the consensus estimate of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.76% and a return on equity of 57.35%. The company had revenue of $998.43 million during the quarter, compared to analysts' expectations of $998.25 million. During the same quarter in the previous year, the company posted $2.71 EPS. The business's revenue for the quarter was up 3.6% compared to the same quarter last year. On average, equities analysts predict that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on IDXX shares. Stifel Nicolaus increased their target price on IDEXX Laboratories from $510.00 to $540.00 and gave the stock a "hold" rating in a research report on Wednesday, July 2nd. Leerink Partners lifted their target price on IDEXX Laboratories from $580.00 to $600.00 and gave the stock an "outperform" rating in a report on Thursday. Morgan Stanley raised their price objective on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research note on Monday, May 5th. Jefferies Financial Group assumed coverage on shares of IDEXX Laboratories in a research report on Tuesday, July 1st. They issued a "buy" rating and a $625.00 price target for the company. Finally, Wall Street Zen upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a report on Saturday, July 12th. Three research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, IDEXX Laboratories presently has a consensus rating of "Moderate Buy" and a consensus target price of $560.33.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.